Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Blood

Volumn 121, Issue 11, 2013, Pages 1961-1967

  Richardson, Paul G ^a   Siegel, David ^b   Baz, Rachid ^c   Kelley, Susan L ^d   Munshi, Nikhil C ^a   Laubach, Jacob ^a   Sullivan, Daniel ^c   Alsina, Melissa ^c   Schlossman, Robert ^a   Ghobrial, Irene M ^a   Doss, Deborah ^a   Loughney, Nora ^a   McBride, Laura ^b   Bilotti, Elizabeth ^b   Anand, Palka ^b   Nardelli, Lisa ^c   Wear, Sandra ^d   Larkins, Gail ^e   Chen, Min ^e   Zaki, Mohamad H ^e   Jacques, Christian ^e   Anderson, Kenneth C ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Multiple Myeloma Research Consortium   (United States)

^e CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; M PROTEIN; POMALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE; THALIDOMIDE;

ABSCESS; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; KIDNEY FAILURE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL PAIN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RASH; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE; TREATMENT FAILURE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877605245     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-450742     Document Type: Article

References (30)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
2. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30): 5008-5014.
3. Kumar SK, Lee JH, Lahuerta JJ, et al. International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1): 149-157.
4. Sinha S, Lacy M, Mikhael J, et al. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia. 2012;26(4):839-841.
5. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11): 2970-2975.
6. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-386.
7. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD341 progenitor cells. Cancer Res. 2007;67(2): 746-755.
8. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9): 2943-2950.
9. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18): 7347-7356.
10. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155-167.
11. Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116(17):3227-3237.
12. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12): 4525-4530.
13. Rychack L, Mendy D, Miller K, et al. Overcoming resistance; the use of pomalidomide and dexamethasone in re-sensitizing lenalidomide-resistant multiple myeloma cells. Haematologica. 2011;96(S1):abstr P328.
14. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16): 3269-3276.
15. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008; 141(1):41-51.
16. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11): 1934-1939.
17. Leleu Y, Attal M, Arnulf B, et al. Phase 2 multicenter, randomized, open-label study of 2 modalities of pomalidomide plus low-dose dexamethasone (POMD) in patients with multiple myeloma (MM), refractory to both lenalidomide and bortezomib (double refractory), IFM 2009-02. Haematologica. 2011;96(S1): abstr P148.
18. Bladé J, Samson D, Reece D, et al. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123.
19. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
20. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
21. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events. version 3.0. http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf
22. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108(10):3458-3464.
23. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009;114(4):772-778.
24. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-3120.
25. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
26. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79(7): 875-882.
27. Siegel DSD, Martin T, Wang M, et al. PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. J Clin Oncol. 2011;29: abstr 8027.
28. Mikhael J, Gertz M, Hayman S, et al. Long-term efficacy and duration of response of pomalidomide in patients with relapsed multiple myeloma. Haematologica. 2011;96(S1):abstr P300.
29. Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist. 2007; 12(6):664-689.
30. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009;27(34):5713-5719.